FDA Adverse Event Injury Summary report: N

NC QUANTUM APEX BALLOON CATHETER

MDR report key: 3606061 · Received February 4, 2014

Report

Report Number
2134265-2014-00322
Event Type
Injury
Date Received
February 4, 2014
Date of Event
January 5, 2012
Report Date
January 16, 2014
Manufacturer
BOSTON SCIENTIFIC - MAPLE GROVE
Product Code
LOX
PMA / PMN Number
K121667
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NC, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

DEVICE EVALUATED BY MFR: THE DEVICE WAS NOT RECEIVED FOR ANALYSIS. THE BATCH NUMBER IS UNKNOWN AND THE MANUFACTURING RECORDS FOR THE COMPLAINT DEVICE COULD NOT BE REVIEWED. THE ROOT CAUSE IS ANTICIPATED PROCEDURAL COMPLICATIONS AS THIS EVENT IS A KNOWN PHYSIOLOGICAL EFFECT OF THE PROCEDURE AND IS NOTED WITHIN THE DFU. (B)(4).

Description of Event or Problem · 1

SAME CASE AS MDR ID # 2134265-2014-00325. (B)(4) CLINICAL STUDY. IT WAS REPORTED THAT A CHEST PRESSURE OCCURRED. IN (B)(6) 2012, THE SUBJECT PRESENTED WITH STABLE ANGINA AND WAS REFERRED FOR CARDIAC CATHETERIZATION AND INDEX PROCEDURE WAS PERFORMED. THE SUBJECT WAS ENROLLED IN THE (B)(4) STUDY. TARGET LESION #1 WAS A IN STENT STENOTIC LESION (UNKNOWN DES) LOCATED IN THE MID LEFT ANTERIOR DESCENDING ARTERY (LAD)WITH 90-95% STENOSIS AND WAS 16 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 3 MM. TARGET LESION WAS TREATED WITH DIRECT STENT PLACEMENT USING A 3.00 MM X 20 MM ION STENT. FOLLOWING POST DILATATION, RESIDUAL STENOSIS WAS 0%. AFTER THE IMPLANTATION OF 3 X 20 MM (B)(4) STUDY STENT AND POST DILATATION WITH 3.25 MM X 12MM NC QUANTUM APEX BALLOON CATHETER, CHEST PRESSURE REPORTED (8/10 ON PAIN SCALE) BY THE SUBJECT. FENTANYL IV 25 MG WAS GIVEN TO TREAT THIS EVENT. THE SUBJECT WAS DISCHARGED THE FOLLOWING DAY ON ASPIRIN AND CLOPIDOGREL.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
71647 NC QUANTUM APEX BALLOON CATHETER CATHETERS, TRANSLUMINAL CORONARY ANGIOPLASTY, PERCUTANEOUS LOX BOSTON SCIENTIFIC - MAPLE GROVE UNK651

Patients

Seq Age Sex Outcome Treatment
1 59 YR Required Intervention